Regulus Therapeutics Inc is a biopharmaceutical company. The Company is engaged in discovering and developing first-in-class drugs that target microRNAs to treat various diseases.
Website: | www.regulusrx.com |
Email: | information@regulusrx.com |
Main Phone: | +1 858 202-6300 |
Address: | 3545 John Hopkins Court |
Address 2: | Suite 210 |
State: | CA |
City / Town: | San Diego |
Country: | USA |
Postal Code: | 92121 |
Exchange: | NSD |
Employees: | 94 |
NAICS: | Pharmaceutical P |
Last Price 0.65 | Change $ -0.0039 | Change % -0.60 | Tick N/A |
Bid 0.64 | Bid Size 100.00 | Ask 0.65 | Ask Size 100.00 |
Open 0.65 | High 0.67 | Low 0.64 | Prev Close 0.65 |
Last Trade | Volume 39,474 | 52 Wk Hi 1.95 | 52 Wk Low 0.63 |
Market Cap 67.5 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
Shares 103,959,103.00 | EPS (TTM) -1.05 | PE Ratio N/A | Exchange NSD |
|
|
Last 3 Mo | Last 12 Mo | |
---|---|---|
Number of Insider Trades | 0 | 1 |
Number of Buys | 0 | 1 |
Number of Sells | 0 | 0 |
Net Activity | 0 | 10000 |
Last 10 Buys | Shares |
---|---|
Joseph P. Hagan | 1,000 |
Mark G. Foletta | 1,000 |
William H. Rastetter | 1,000 |
William H. Rastetter | 1,000 |
Stanley T. Crooke | 1,000 |
B. Lynne Parshall | 1,000 |
Last 10 Sell | Shares |
---|---|
Kleanthis G. Xanthopoulos | 1,000 |
Kleanthis G. Xanthopoulos | 1,000 |
Kleanthis G. Xanthopoulos | 1,000 |
Bruce L.A. Carter | 1,000 |
Kleanthis G. Xanthopoulos | 1,000 |
Kleanthis G. Xanthopoulos | 1,000 |
Kleanthis G. Xanthopoulos | 1,000 |
Kleanthis G. Xanthopoulos | 1,000 |
Kleanthis G. Xanthopoulos | 1,000 |
Kleanthis G. Xanthopoulos | 1,000 |
Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
---|---|---|---|---|
High Target Price Estimate | 15 | 15 | 15 | 15 |
Low Target Price Estimate | 4 | 4 | 4 | 4 |
Mean Target Price Estimate | 10 | 10 | 10 | 10 |
Standard Deviation | 4.06 | 4.06 | 4.06 | 4.06 |
Date of Most Recent Estimate | 08/03/16 | 08/03/16 | 07/25/16 | 08/23/16 |
Form Type | Form Description | Pages | Date |
---|---|---|---|
10-Q | Quarterly report with a continuing view of a company's financial position | 110 | 2016-08-03 |
8-K | Report of unscheduled material events or corporate changes. | 8 | 2016-08-02 |
8-K | Report of unscheduled material events or corporate changes. | 3 | 2016-06-27 |
8-K | Report of unscheduled material events or corporate changes. | 3 | 2016-06-23 |
8-K/A | Amendment to a previously filed 8-K | 3 | 2016-06-14 |
8-K | Report of unscheduled material events or corporate changes. | 29 | 2016-06-08 |
8-K | Report of unscheduled material events or corporate changes. | 3 | 2016-06-07 |
4 | Statement of changes in beneficial ownership of securities | 1 | 2016-06-03 |
4 | Statement of changes in beneficial ownership of securities | 1 | 2016-06-03 |
4 | Statement of changes in beneficial ownership of securities | 1 | 2016-06-03 |
Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|
Strong Buy | 5 | 5 | 6 | 7 |
Moderate Buy | 1 | 1 | 0 | 0 |
Hold | 1 | 1 | 0 | 0 |
Moderate Sell | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 |
Mean Rec. | 1.43 | 1.43 | 1 | 1 |